Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-01-31
2006-01-31
Le, Long V. (Department: 1641)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C435S006120, C435S007210, C435S007230, C436S813000, C436S819000, C424S001690, C424S001890, C424S009321, C514S002600, C514S012200, C514S013800, C514S014800, C514S073000, C514S078000, C530S388200, C530S388800, C530S388850, C530S389700
Reexamination Certificate
active
06991776
ABSTRACT:
New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.
REFERENCES:
patent: 4647578 (1987-03-01), Crounse et al.
patent: 4846789 (1989-07-01), Heitz et al.
patent: 5552452 (1996-09-01), Khadem et al.
patent: 6331286 (2001-12-01), Dees et al.
patent: WO 99/45869 (1999-06-01), None
patent: WO 00/25665 (2000-05-01), None
patent: WO 00/43045 (2000-07-01), None
Search Report for Application No. EP 01 92 6602 dated May 14, 2003.
Office Action dated Dec. 3, 2004 for U.S. Appl. No. 09/817,448.
Wilson et al., “Enhancement of Tumor Radiation Response by the Anivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid,” Int. J. Radiation Oncology Biol. Phys., vol. 42, No. 4, pp. 905-908, (1998).
Dees H. Craig
Fisher Walter G.
Scott Timothy C.
Smolik John
Wachter Eric A.
Cook Alex McFarron Manzo Cummings & Mehler, Ltd.
Gabel Gailene R.
Le Long V.
Xantech Pharmaceuticals, Inc.
LandOfFree
Intracorporeal medicaments for high energy phototherapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intracorporeal medicaments for high energy phototherapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intracorporeal medicaments for high energy phototherapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3589721